Delhi HC Permits Dr Reddy’s to Make and Export Ozempic Analogues

Introduction On 2 December 2025 the Delhi High Court refused an interim injunction sought by Danish pharmaceutical giant Novo Nordisk and allowed Dr Reddy’s Laboratories to continue manufacturing and exporting a semaglutide-based weight-loss/diabetes drug marketed globally as Ozempic. The litigation, driven by allegations of patent infringement, raised immediate questions about the scope of patent protection, territoriality of rights, and the proper balance between proprietary exclusivity and public interest in access to medicines. The ruling is legally important because it tests the boundaries of interim relief in pharmaceutical patent disputes and underscores how courts weigh commercial harm to right‑holders against the availability of alternative remedies and the realities of a global generics supply chain.

Legal Background India’s patent regime is governed by the Patents Act and domestic jurisprudence shaped by landmark disputes — for example, Novartis v. Union of India on inventive step and patentability, and the Natco–Bayer compulsory licence proceedings on public interest and access to medicines. Key legal principles that govern interim injunctions in patent disputes include: (i) whether the claimant has a prima facie case of validity and infringement; (ii) whether the balance of convenience favors grant of relief; and (iii) whether the claimant will suffer irreparable harm that cannot be compensated by damages.

Patent rights are territorial: a patent granted in one jurisdiction does not automatically confer rights in another. Courts also consider the commercial realities of pharmaceutical manufacture — such as whether the accused product is destined for export to countries where the patent is not in force — and whether alternative legal remedies (seizure at export ports, customs action, or an account of profits) can adequately protect the patentee. International law and policy debates — including TRIPS flexibilities and the Doha Declaration on public health — inform but do not displace statutory rights granted by national law.

Critical Analysis The Delhi High Court’s decision to refuse an interim injunction appears to rest on a conventional tripartite interim injunction analysis: a weak prima facie case on the patent’s validity or infringement; a finding that damages would be an adequate remedy; and the balance of convenience tipping in favour of the defendant. In pharmaceutical patent litigation, courts are often reluctant to grant a freezing injunction where the product is manufactured for export and where the alleged infringement depends upon complex validity challenges that are best resolved at trial.

Territoriality is central. If Dr Reddy’s products are intended for markets where Novo Nordisk’s patent does not subsist, then Indian courts are less inclined to shut down lawful activity taking place within India. The patent holder must demonstrate a realistic risk of market diversion into territories where it retains exclusive rights. Absent such a showing, the court can reasonably conclude that an injunction would cause disproportionate economic harm — to the manufacturer, trading partners, and patients in importing countries — while the patentee’s monetary remedy would suffice if validity is ultimately upheld.

The court likely scrutinised the strength of Novo Nordisk’s prima facie case on validity. Semaglutide and related formulations have been the subject of extensive patenting; alleged inventive step or obviousness deficiencies are often complex, with prior art and technical expert evidence tipping the scales. Where the patent’s validity is in credible doubt, courts historically refuse interlocutory relief (a principle evident in several Indian and Commonwealth precedents). The availability of alternative remedies — for instance, customs interception of infringing consignments at ports of export, or the award of damages and an account of profits — reduces the need for an interim injunction.

Potential human‑rights and public‑interest considerations also influence the analysis. Although this case concerned a lucrative weight‑loss drug rather than a life‑saving medicine, Indian courts have consistently privileged access-to-medicines principles in patent disputes. Wholesale interruption of manufacturing and export lines can have cascading effects on global supply chains and patients’ access to affordable medicines in markets relying on Indian generics.

If details are missing: the public reports do not specify whether exports were destined for specific countries with or without valid semaglutide patents, nor whether preliminary technical expert reports were filed. Those facts would materially affect the strength of Novo Nordisk’s case and the court’s interim calculus.

Opinion & Outlook The Delhi High Court’s stance reinforces a measured approach to interlocutory relief in pharmaceutical patent disputes. Practically, patentees must present a robust prima facie case on both validity and infringement, and demonstrate that monetary compensation would be inadequate and that irreparable harm is likely. Where defendants can show manufacture-for-export and identify substantial questions on validity, courts will favour maintaining commercial activity subject to later adjudication and compensatory remedies.

For patent holders, this decision signals the importance of bespoke relief strategies: pursuing customs-based enforcement, expedited trials, or border measures in importing jurisdictions, rather than seeking broad manufacturing injunctions in India. For generics manufacturers, the judgment affirms the cautious leeway available in producing for export, provided supply chains are transparent and compliant with local and international law.

Law reform and policy actors should note the friction between territorial patent rights and globalised pharmaceutical manufacturing. Consideration could be given to clearer statutory pathways for interim border measures, faster patent trial timetables in high-stakes pharmaceutical cases, and guidance on how courts should weigh public interest and access-to-medicines considerations when interlocutory relief is sought.

Conclusion The Delhi High Court’s refusal of an interim injunction in the Novo Nordisk–Dr Reddy’s dispute illustrates the judiciary’s pragmatic balancing of proprietary rights against commercial realities and public interest. By emphasising the need for a strong prima facie case and adequate alternative remedies, the ruling preserves manufacturing and export activity while leaving substantive rights to be resolved at trial. The decision will shape enforcement strategies in future pharmaceutical patent litigation and highlights an ongoing tension between territorial patent exclusivity and an integrated global supply chain.